I like the business model description of CGEN found at an Investor Place article because I’ve spent some time with pharmaceutical and biotech companies and know how they rely on this type of data. But, like most articles I find there, they are touting the stock on the upswing and I need a dip to be cheap (lazy covered by them doing the research for me).